Meet some of Alberta’s top Medical Device, Diagnostic and HealthIT technologies and companies who are coming to connect with the investment community in Boston. They are going head to head with some of Massachusetts top startups!
Join us for a night of learning about game-changing medical device companies making strides today. This pitch event, sponsored by BioAlberta, will take place from 5:30–6pm. There will be 5 medical device companies making 3 minute pitches and afterwards, guests are encouraged to continue the conversations one on one.
BioAlberta is a member-driven association that represents and promotes the province’s vibrant and diverse life sciences industry. Through their many partnerships and collaborations, they are dedicated to promoting Alberta’s life science sectors, locally, nationally and internationally.
Canadian Companies Pitching:
Metabolomic Technologies (MTI)– $25M Series B
Metabolomic Technologies Inc.(MTI) is engaged in using the new science of metabolomics to deliver innovative non-invasive diagnostics to the healthcare market. MTI’s flagship product, PolypDx™, is the first and only urine-based test with a high sensitivity for detecting adenomatous polyps, the precursor to colorectal cancer, thus providing doctors with a new tool for early screening and detection.
Salu Health Gauge– $0.5-2M Seed
Due to the global problem of hypertension – and related health problems – Salu created Health Gauge: a wearable to measure blood pressure and other important biometrics (including ECG, PPG, oxygen saturation, heart rate, and heart rate variability), along with an AI-based platform solution to support people in tracking, understanding, and managing their health. Currently, Health Gauge is working on new research proects including a project with the rehabilitation of stroke patients with Alberta Health Services (Glenrose Rehabilitation), and a study on eclampsia in developing nations with ICDDR,B (Bangladesh) supported by the Bill and Melinda Gates Foundation.
Tevosol– $20M Series A
Tevosol, Inc. is a medical device company developing the Ex-Vivo Organ Support System (EVOSS™) with the goal of increasing the number of organs available for transplantation worldwide. The EVOSS™ is a warm organ perfusion device consisting of a hardware platform with organ-specific single-use disposable cassettes for lungs, hearts, livers, and kidneys intended to preserve and assess viability of organs for transplant.
Strand Therapeutics – MIT 100K Finalist – Seed
As a platform, gene therapy has long held the promise of expressing therapeutics proteins directly inside our own bodies. In previous generations, companies focused on DNA delivery without controlled gene expression. In more recent years, RNA therapeutics have emerged as safer, easier to deliver alternative gene delivery vectors. Strand Therapeutics exists at the intersection between synthetic biology and RNA therapeutics: the only company that has built the genetic programming language of RNA to precisely control the expression of RNA therapeutics and deliver truly revolutionary treatments.
The Ocelot™ product is a novel, comprehensive system for performing percutaneous tenotomy and consists of a hand-held reusable unit, a single-use disposable component, and real-time feedback for the physician to assess the effectiveness of the intervention. It has been designed to be a cost-effective tool for treatments that can be performed in a clinician’s office. The result is a system that improves the patient experience, reduces cost/procedure, with the benefit of improved outcomes.
This session is part of Mission to Boston: Sponsored by Bio Alberta.
BioAlberta is a member-driven association that represents and promotes the province’s vibrant and diverse life sciences industry. Through their many partnerships and collaborations, they are dedicated to promoting Alberta’s life science sectors, locally, nationally and internationally. Join us for a night of learning about their recent efforts, as well as pitches from several of their medical device companies!